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A global regulator of chromatin remodelling and gene expression, special AT-rich-binding protein
1 (SATB1) has been implicated in promotion of growth and metastasis of a number of cancers.
Here, we demonstrate that the principal oncogene of Epstein–Barr virus (EBV), latent membrane
protein 1 (LMP1) upregulates SATB1 RNA and protein expression in human nasopharyngeal cell
lines. Silencing of endogenously expressed SATB1 with specific short hairpin RNA decreases cell
proliferation and resistance to apoptosis induced by growth factor withdrawal. Additionally, we
provide evidence that LMP1-mediated expression of Survivin, a multifunctional protein involved in
promoting cell growth and survival, is mediated at least in part by SATB1 in human
nasopharyngeal cells. Finally, we show that SATB1 protein levels are elevated in tissue samples
from patients with nasopharyngeal carcinoma (NPC), and are directly correlated with the
expression of LMP1. Taken together, our results suggest that SATB1 functions as a pro-
metastatic effector of LMP1 signalling in EBV-positive NPC.
Special AT-rich sequence-binding protein 1 (SATB1) was
originally identified as protein binding to matrix attach-
ment regions (MARs) of unpaired DNA (Dickinson et al.,
1992; Sun et al., 2006). SATB1 was shown to regulate
distant genes by selectively tethering MARs to the nuclear
matrix, resulting in the formation of a characteristic ‘cage-
like’ network that circumscribes heterochromatin (Cai
et al., 2003). Furthermore, SATB1 acts as a ‘docking site’
for several chromatin modifiers (Kumar et al., 2005; Yasui
et al., 2002), and these chromatin modifiers were suggested
to suppress gene expression through histone deacetylation
and nucleosome remodelling at SATB1-bound MARs
(Yasui et al., 2002). Phosphorylation of SATB1 might act
as a molecular switch in determining whether the protein
acts as a transcriptional activator or repressor (Pavan
Kumar et al., 2006). Recently, SATB1 has attracted
considerable attention due to its elevated expression in
advanced stages of various types of malignant tumours,
such as breast, gastric, colorectal and laryngeal carcinomas,
which suggests a crucial role in promoting tumour
invasion and metastasis (Cheng et al., 2010; Han et al.,
2008; Iorns et al., 2010; Lu et al., 2011; Meng et al., 2012;
Patani et al., 2009; Shushan et al., 2009; Zhao et al., 2010;
Zheng, 2008). However, although there are reports that
SATB1 regulates transcription of genes that have direct
impact on cellular proliferation and apoptosis (Alvarez
et al., 2000; Kumar et al., 2007), the mechanism by which
SATB1 regulates these phenomena is still unclear and even
controversial (Iorns et al., 2010; Li et al., 2007).
Nasopharyngeal carcinoma (NPC) is the most common
Epstein–Barr virus (EBV)-associated tumour, and it is
noteworthy for its proclivity to early invasion and metastasis
(Burgos, 2005; Pagano, 2009; Wakisaka & Pagano, 2003;
Zheng et al., 2007). The principal EBV oncoprotein LMP1, a
member of the tumour necrosis factor receptor superfamily,
is detected in at least 70 % of NPC cases, and is considered to
be the main mediator of the oncogenic properties of EBV in
the development of NPC and its metastasis (Marquitz &
Raab-Traub, 2012; Tsao et al., 2002b; Wakisaka & Pagano,
2003; Yoshizaki et al., 2005). In a series of reports we have
shown that LMP1 induces expression of a variety of cell-
invasiveness and angiogenic factors and explored their
effects in nasopharyngeal (NP) cells in culture (Yoshizaki
et al., 1998; Kondo et al., 2005; Wakisaka et al., 2002;
Murono et al., 2001; Wakisaka et al., 2004; Kondo et al.,
2006, 2007; Horikawa et al., 2007). Since recent studies
demonstrate that SATB1 promotes tumour growth and
metastasis in several carcinomas (Lu et al., 2011; Meng et al.,
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2012; Patani et al., 2009; Tu et al., 2012; Zhao et al., 2010),
we hypothesized that LMP1 upregulates expression of
SATB1 in EBV-positive NPC cells.
First, we examined the endogenous levels of SATB1 and
LMP1 in two sets of EBV-infected cell lines: one set,
epithelial-like cell lines with type II EBV latency obtained by
fusion of a human type III EBV latency lymphoblastoid cell
line with epithelial Hela cells (Contreras-Brodin et al., 1991);
and another, EBV-infected breast cancer cell lines that
express different levels of LMP1 (Arbach et al., 2006;
Horikawa et al., 2007). Western blot analysis shows that the
levels of SATB1 protein are significantly higher in the fused
LMP1-expressing cells KH-1 and KH-2, than in the EBV-
negative parental Hela cells (Fig. 1a), and that the expression
of SATB1 is also upregulated in the LMP1-positive breast
cancer clones C1D12, C2G6 and C3B4, compared with
either the EBV-infected, but LMP1-negative, C4A3 cells or
the uninfected parental line, MDA-MB-231 (Fig. 1b). These
data illustrate the direct correlation between endogenous
LMP1 and SATB1 protein levels in different EBV-positive
carcinoma-derived cell lines.
To investigate whether LMP1 alone can induce SATB1
expression, we transiently transfected LMP1 into two EBV-
negative human NP cell lines, Ad-AH (Takimoto et al.,
1988) and NP69 (Tsao et al., 2002b) and observed
significant increases in levels of SATB1 protein and RNA
in both sets of cell lines (Fig. 1c). To confirm these
observations further we showed that transient overexpres-
sion of LMP1 into Ad-AH cells induces SATB1 in a dose-
dependent manner (Fig. 1d). Moreover, fluorescence
immunostaining revealed much higher levels of SATB1
protein in LMP1-expressing cells (Fig. 1e) (we did not
observe any effects of the empty vector on SATB1
endogenous levels). Taken together these results dem-
onstrate that LMP1 upregulates SATB1 RNA and protein
expression in NP cells.
Two LMP1 intracellular signalling domains, the C-terminal
regulatory regions of the protein, CTAR1 and CTAR2, are
well established as major transmitters of LMP1-induced
signalling pathways involved in initiation and maintenance
of malignant potential in EBV-associated cancers including
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Fig. 1. Expression of SATB1 is increased in EBV latently infected cells. Increase in endogenous SATB1 protein levels
correlates with the levels of the EBV primary oncogene LMP1 in EBV-positive fusion cervical carcinoma cells (a) and in EBV-
infected breast cancer cell lines (b). Transient transfection of SATB1 served as a positive control. EBV primary oncogene LMP1
induces expression of endogenous SATB1 in human NP epithelial cell lines. Stable exogenous expression of LMP1 in Ad-AH
and NP69 cells increases endogenous levels of SATB1 protein (c, top panel) and RNA (c, bottom panel). Dose-dependent
upregulation of endogenous SATB1 by LMP1 overexpression in Ad-AH cells (d). Both CTAR1 and CTAR2 regions of LMP1 are
involved in LMP1-mediated induction of SATB1 gene expression (e). Immunofluorescence analysis showing elevated levels of
endogenous SATB1 protein in LMP1-transfected Ad-AH cells (f).
K. Endo and others
508 Journal of General Virology 94
2002; Izumi, 2004; Lam & Sugden, 2003; Li & Chang, 2003;
Morris et al., 2009; Soni et al., 2007; Tsao et al., 2002a; Zheng
et al., 2007). Fig. 1(e) shows that transfections of LMP1
inactive mutants with point mutations in CTAR1 (LMP1-
PQAA) and CTAR2 (LMP-IID) (Mainou et al., 2007)
reduced SATB1 RNA levels, indicating that LMP1-dependent
expression of SATB1 most probably depends on activation of
multiple signalling pathways from both CTAR1 and CTAR2
domains of LMP1.
Many studies, including ours, demonstrate that LMP1
expression induces an invasive phenotype in NP cells
(Pagano, 2009; Tsao et al., 2002a; Zheng et al., 2007). To
determine whether SATB1 is required for oncogenic
properties of LMP1-expressing NP cells we generated a
stable NP cell line in which SATB1 expression was
suppressed with short hairpin RNA (shRNA) targeting
SATB1 [pSuper-puro vector with SATB1 shRNA was the
kind gift of Dr Hye-Jung Han (Han et al., 2008)]. First, we
analysed cell growth with the 3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetra-
zolium salt (MTS) assay. Growth curves are presented with
the standard deviations (SD) as error bars. As shown in Fig.
2(a), silencing of the SATB1 gene with specific shRNA
significantly reduced growth of LMP1-expressing NP69
cells, but had minimal effect on the parental NP69 cell line.
Deprivation of growth factors leads to cell-cycle arrest
following the induction of apoptosis (Lo et al., 2003; Zhang
et al., 2008a). We tested the ability of SATB1 to protect the
cells from effects induced by growth factor withdrawal by
measuring cell viability of control and NP69 cells
expressing SATB1 shRNA, cultivated in medium without
growth-factor supplements (Fig. 2b). For the first 7 days all
cell lines demonstrated some increase in cell growth, but
eventually underwent starvation-induced cell-cycle arrest.
As expected, LMP1-expressing cells were more resistant to
growth factor withdrawal than parental NP69 cells, which
is consistent with a previous report (Lo et al., 2003). While
the difference in survival between parental NP69 cells
expressing control and SATB1 shRNAs was minimal,
resistance to growth factor withdrawal was significantly
decreased by SATB1 shRNA in NP69-LMP1 cells (Fig. 2b).
The differences in cell growth and apoptosis between NP69
cell clones were analysed by the paired Student’s t-test.
Error bars indicate SD of the mean and significance was
defined at the level of P,0.05.
Our results indicate that SATB1 participates in the
proliferation and survival of NP epithelial cells, most
probably through induction of pro-mitotic and anti-
apoptotic factors. One such factor that mediates prolifera-
tion, invasion and metastasis of many cancers is Survivin.
Originally discovered as an inhibitor of apoptosis, Survivin
also promotes cell proliferation and enhances invasion
(Cheung et al., 2011; Church & Talbot, 2012; Kanwar
et al., 2010, 2011; Lladser et al., 2011). Absent in most adult
tissues, Survivin is selectively upregulated in many human
carcinomas including NPC and correlates with poor
prognosis (Fukayama et al., 2008; Hino et al., 2008; Lippert
et al., 2007; Margulis et al., 2008; McGuire & Fitzpatrick,
2009; Mori et al., 2007; Shi et al., 2006; Zhang et al., 2008b).
Survivin is also a well known target of LMP1-mediated
activation of cell signalling: LMP1 activates the survivin gene
through several signalling pathways, and both CTAR1 and
CTAR2 domains are required (Brinkmann & Schulz, 2006).
To investigate whether the inhibitory effects on cell growth
and survival we observed with suppression of SATB1 (Fig.
2a and b) correlate with the expression of Survivin, we
compared endogenous levels of Survivin protein in NP
NP69 cells under control conditions and with suppressed
levels of SATB1 (Fig. 2c). Western blot analysis shows that
inhibition of SATB1 expression with shRNA resulted in
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Fig. 2. Expression of SATB1 is required for growth and survival of
NP cells. Reduction of SATB1 expression with specific siRNA
inhibits proliferation of NP69 and NP69-LMP1 cells (a). Reduction
of SATB1 levels results in reduced resistance of NP69 and NP-
LMP1 cells to growth factor withdrawal (b). Inhibition of SATB1
expression correlates with the reduction of LMP1-induced levels of
anti-apoptotic protein Survivin in NP69 cells (c). Student’s t test:
*, P50.0019, compared with NP69 control siRNA cells.
**, P50.0097, compared with NP69-LMP1 control siRNA cells.
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some reduction in Survivin levels, and this effect was much
more profound in the presence of LMP1: inhibition of
SATB1 expression resulted in a significant reduction of
Survivin in LMP1-positive NP69 cells. Different EBV
products induce the expression of Survivin through
different mechanisms (Bai et al., 2005; Lu et al., 2011;
Paydas et al., 2009; Slovin et al., 1981), and our data
indicate that SATB1 is directly or indirectly involved in
LMP1-mediated upregulation of Survivin. In the future we
plan to investigate the mechanisms of such upregulation.
Finally, we tested whether there is a correlation between
SATB1 and LMP1 expression in EBV-positive tumour
tissue samples from NPC patients. Ten randomly selected
NPC paraffin-embedded specimens from Kanazawa
University Hospital (Ishikawa, Japan) were used for the
detection of LMP1 and SATB1. Specimens obtained at
biopsy were from eight men and two women, ages 45–
78 years (mean 58.7 years), and classified histologically as
follows: five non-keratinizing carcinoma (type II) and five
undifferentiated carcinoma (type III) [5th TNM classifica-
tion system of the International Union Against Cancer
(1997)]. There were two stage IIB, seven stage III and one
stage IVC. SATB1 levels were examined by immunohisto-
chemistry in the NPC tissues of the ten patients (Fig. 3).
Pearson’s correlation coefficient was used to detect
correlations among the expression scores of each protein
analysed in NPC. The expression score of each protein in
relation to clinical data was analysed with the Mann–
Whitney U-test as described previously (Horikawa et al.,
2011). Expression scores for SATB1 and LMP1 are closely
correlated (r50.731; P,0.001). These data demonstrate a
significant in-vivo correlation between LMP1 and SATB1
levels in NPC, which supports the hypothesis that
expression of SATB1 is associated with a highly aggressive
and metastatic phenotype of several human carcinomas
(Han et al., 2008; Kuo & Chao, 2010; Peng et al., 2011; Tu
et al., 2012).
Recently, we showed that LMP1 contributes to the cancer
progenitor-like phenotype of NPC (Kondo et al., 2011),
and that SATB1 is required for proper stem-cell differ-
entiation and negatively regulates pluripotency genes
(Savarese et al., 2009). Considering that SATB1 expression
is lost as the progenitor cells further differentiate (Agrelo &
Wutz, 2009; Wen et al., 2005), it is possible that expression
of SATB1 is part of an embryonic pathway for establishing
epigenetic patterns that are reactivated in somatic pro-
genitors (Agrelo & Wutz, 2009). Upregulation of SATB1 by
LMP1 strengthens these recent findings, and SATB1 could
have some role in the context of the cancer stem/
progenitor cell axis in the oncogenesis of NPC. The data
presented here underscore also a series of findings that
support the contribution of LMP1 to upregulation of
metastasis via inducing epithelial mesenchymal transition
(EMT) (Horikawa et al., 2007, 2011).
SATB1 expression and the ability of Xist induction to
initiate X chromosome inactivation are two aspects that
provide a link between the epigenetic context of embryonic
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Fig. 3. Correlation between SATB1 and LMP1
expression in EBV-positive NPC tissues.
Immunohistochemical detection of SATB1
and EBV LMP1 in human NP carcinoma
tissues (a). Regression analysis shows the
significant correlation between expression of
SATB1 and LMP1 in the ten NPC specimens
obtained at biopsy (b).
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(Agrelo et al., 2009). Haematopoietic progenitors are
probably at a critical transition when cell identity is
unstable. This epigenetic context thus defines the biology
of a class of cancer progenitors that distinguishes them
from normal cells and could be a novel target for cancer
therapies. The data presented here underscore also a series
of findings that support the contribution of LMP1 to
upregulation of metastasis via inducing EMT (Horikawa
et al., 2007, 2011). Induction of SATB1 by LMP1 in
epithelial cells sheds light on a more precise role of LMP1
in the cancer stem cell theory (Kondo et al., 2011). It will
be of interest to investigate the clinical implications of
LMP1-mediated SATB1 induction in future studies.
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